Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Courtney Regan Wagner"'
Autor:
Jessica Fleser, Bernard A. Fox, Annika Dalheim, David C. Murray, Chris Fountain, Constantine Godellas, Tamson V. Moore, Brendan D. Curti, Joseph I. Clark, Jodi Speiser, Siao Yi Wang, Michael I. Nishimura, Mallory Thomas, Matthew DeJong, Courtney Regan Wagner, Tarsem Moudgil, Gina Scurti, Kelli A. Hutchens
Publikováno v:
Molecular Therapy: Oncolytics, Vol 20, Iss, Pp 352-363 (2021)
Molecular Therapy Oncolytics
Molecular Therapy Oncolytics
T cells that are gene-modified with tumor-specific T cell receptors are a promising treatment for metastatic melanoma patients. In a clinical trial, we treated seven metastatic melanoma patients with autologous T cells transduced to express a tyrosin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8013b10b214b2316e2f365a86b70c5ea
http://www.sciencedirect.com/science/article/pii/S2372770521000152
http://www.sciencedirect.com/science/article/pii/S2372770521000152
Publikováno v:
Journal of Clinical and Medical Case Reports. :1-5
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have demonstrated improved progression-free survival benefits and decreased treatment-related side effects, and therefore are now considered first-line of treatment of EGFR mutat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e683a20f19b38018d8cbfa01bb98b3ba
https://doi.org/10.31487/j.jcmcr.2020.02.06
https://doi.org/10.31487/j.jcmcr.2020.02.06
Autor:
Joseph I. Clark, Jose Guevara, Stephanie Berg, Blaine A. Knox, Lourdes Plaza-Rojas, Michael Delos Reyes, Cara Joyce, Kushal Prajapati, Daniel Linden, Courtney Regan Wagner, Cynthia Perez, Elizabeth Elliott, Brianna Burke
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Humans are genetically diverse and possess a rich immunological history. It is logical to consider that these factors may lead to differences in individual immunological responses to therapy when diagnosed with cancer. The successful imple
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a97dada8e0e2135b3f9cf843bc0c6bea
https://doi.org/10.1136/jitc-2020-sitc2020.0052
https://doi.org/10.1136/jitc-2020-sitc2020.0052
Autor:
Constantine Godellas, Patrick J. Stiff, Courtney Regan Wagner, Ann Lau Clark, Emilia R. Dellacecca, Kelli A. Hutchens, Mingli Li, Elizabeth Garrett-Mayer, Joseph I. Clark, I. Caroline Le Poole, Keisuke Shirai, Kelly M. Calabrese, Boro Dropulic, Rimas Orentas, Fernando A. Huyke, Heather Embree, Elizabeth Motunrayo Kolawole, Lance M. Hellman, Brian M. Baker, Gina Scurti, Jonathan M. Eby, Nishant K. Singh, Tamson V. Moore, Michael I. Nishimura, Brian D. Evavold, Siao Yi Wang
Publikováno v:
Cancer Immunol Immunother
Malignant melanoma incidence has been increasing for over 30 years, and despite promising new therapies, metastatic disease remains difficult to treat. We describe preliminary results from a Phase I clinical trial (NCT01586403) of adoptive cell thera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::479098ff93f29538a5a02b5eb230caa7
https://pubmed.ncbi.nlm.nih.gov/29264697
https://pubmed.ncbi.nlm.nih.gov/29264697
Autor:
Brianna Burke, Courtney Regan Wagner, Michael Wesolowski, Jose Guevara, Stephanie Berg, Joseph I. Clark
Publikováno v:
Journal of Clinical Oncology. 37:e14037-e14037
e14037 Background: Immune-related adverse events (irAEs) related to immune checkpoint inhibitors (ICIs) may target any organ and originate from autoreactive T cells injuring host tissues. There is a need to develop prognostic and predictive biomarker
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1d4af3c89bbfa42afccf5f2aa43f8d97
https://doi.org/10.1200/jco.2019.37.15_suppl.e14037
https://doi.org/10.1200/jco.2019.37.15_suppl.e14037
Autor:
Elizabeth Henry, Courtney Regan Wagner, Stephanie Berg, Robert C. Flanigan, Hanh P. Mai, Joseph I. Clark
Publikováno v:
Journal of Clinical Oncology. 37:14-14
14 Background: Approved treatments for metastatic melanoma (MM) and metastatic renal cell carcinoma (mRCC) include targeted agents, high dose interleukin-2 (HD IL-2) and checkpoint inhibitors (CI). A subset of responders to HD-IL2 can achieve long te
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4b7c2e0537346b5fca5b14d69b7eb9f9
https://doi.org/10.1200/jco.2019.37.8_suppl.14
https://doi.org/10.1200/jco.2019.37.8_suppl.14
Autor:
Courtney Regan Wagner, I. Caroline Le Poole, Boro Dropulic, Michael I. Nishimura, Mingli Li, Heather Embree, Jonathan M. Eby, Brian D. Evavold, Elizabeth Motunrayo Kolawole, Constantine Godellas, Fernando A. Huyke, Brian M. Baker, Keisuke Shirai, Kelly M. Calabrese, Siao Yi Wang, Lance M. Hellman, Ann Lau Clark, Emilia R. Dellacecca, Gina Scurti, Rimas Orentas, Elizabeth Garrett-Mayer, Patrick J. Stiff, Tamson V. Moore, Nishant K. Singh, Kelli A. Hutchens, Joseph I. Clark
Publikováno v:
Cancer Immunology, Immunotherapy. 67:327-327
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c4ebbe0782a0a094e8d836bfe4171003
https://doi.org/10.1007/s00262-017-2102-z
https://doi.org/10.1007/s00262-017-2102-z